Sign into an existing account

Pfizer said in a statement to NBC News it anticipates results on its clinical trials in kids ages 5 to 11 sometime in September, and then could apply for emergency use authorization. "Data for kids 2 and under 5 could arrive soon after that," the company said, adding that results on kids ages 6 months up to 2 years may not be released until October or November.

Dr. Buddy Creech, one of the primary researchers for the Moderna KidCOVE clinical trials, which includes children as young as 6 months, predicted a rollout of pediatric data similar to Pfizer's.

"I can't imagine, except maybe for the 6- to 11-year-olds, that we're going to have too much data before the late fall," Creech, also a pediatric infectious disease expert and director of the Vanderbilt Vaccine Research Program at the Vanderbilt University Medical Center in Nashville, Tennessee, said.